Perimeter Medical Imaging AI to Start OTCQX Trading
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) is thrilled to announce that its common shares will commence trading on the OTCQX Best Market under the symbol 'PYNKF'. This transition is effective from the opening of business on February 27, 2025.
Enhancing Visibility with OTCQX Listing
In a statement, Perimeter's Chief Executive Officer, Adrian Mendes, highlighted the motivation behind this move. 'Many of our shareholders are based in the United States, which is also our primary target market for the current S-Series OCT system and our new AI-enabled B-Series product,' he said. This listing on OTCQX signifies a natural evolution for Perimeter, aimed at boosting visibility and expanding the U.S. shareholder base.
This step reflects Perimeter's commitment to providing advanced imaging technology designed to enhance cancer surgery outcomes. The Company has gained recognition for its innovative approaches that facilitate better decision-making during surgeries.
Pioneering Technological Advancements
In a pivotal study conducted in late 2024, Perimeter reported promising topline results that support the planned submission for U.S. Food and Drug Administration (FDA) premarket approval for its next-generation B-Series with ImgAssist AI 2.0. This product is specifically developed for use during breast-conserving surgeries. Significantly, the study achieved its primary endpoint, demonstrating a reduction in residual cancer presence during surgical procedures. These positive results underscore the efficacy of the Perimeter B-Series OCT system in assisting surgeons achieve optimal outcomes, potentially reducing the likelihood of reoperations.
Continuing Operations on TSX Venture
While Perimeter shifts its trading operations, its common shares will continue to trade on the TSX Venture Exchange under the existing symbol 'PINK'. This dual listing is expected to enhance market presence and shareholder engagement.
About Perimeter Medical Imaging AI, Inc.
Headquartered in Canada and Texas, Perimeter Medical Imaging AI, Inc. is committed to revolutionizing cancer surgery through the development of ultra-high-resolution, real-time imaging tools. The FDA-cleared Perimeter S-Series OCT system offers unparalleled insight into excised tissues at the cellular level, providing surgeons with critical information during procedures. The upcoming B-Series OCT with ImgAssist AI, which is under investigation, has been recognized for its potential to significantly improve surgical outcomes and is backed by a considerable grant awarded by the Cancer Prevention and Research Institute of Texas.
Innovative Solutions for Unmet Medical Needs
Perimeter aims to address significant unmet medical needs in cancer care through its advanced imaging solutions. The pink color in the Company's ticker symbol 'PINK' represents the widespread campaign for Breast Cancer Awareness Month, reflecting the Company’s commitment to cancer awareness and improved patient care.
Frequently Asked Questions
What is the significance of Perimeter's OTCQX listing?
The OTCQX listing enhances Perimeter's visibility and accessibility to U.S. investors, providing a broader platform for trading its shares.
What are the expected benefits of the B-Series OCT with ImgAssist AI?
This next-generation system aims to assist surgeons more effectively in achieving clear margins during breast cancer surgeries, potentially reducing the need for reoperations.
How does the Perimeter S-Series OCT system work?
The S-Series employs advanced imaging technology to provide real-time, cross-sectional visualization of excised tissues, enabling better surgical decision-making.
What is the funding status of Perimeter?
The Company has received up to $7.4 million in grants to support its research and development efforts, enhancing its ability to innovate effectively.
Where can I find more information about the B-Series OCT?
For additional information, you can visit Perimeter's official website and review their disclosures regarding the investigational status and application of their technologies.
